Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort

World Journal of Urology

Volumn 33, Issue 6, 2015, Pages 833-839

  Höfner, Thomas ^a   Vallet, Sonia ^a   Hadaschik, Boris A ^a   Pahernik, Sascha ^a   Duensing, Stefan ^a   Hohenfellner, Markus ^a   Jäger, Dirk ^a   Grüllich, Carsten ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Abiraterone acetate; Chemotherapy; Docetaxel; Metastatic prostate cancer; Survival

Indexed keywords

ABIRATERONE; ANDROSTANE DERIVATIVE; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BICALUTAMIDE; BUSERELIN; DOCETAXEL; FLUTAMIDE; LEUPRORELIN; NITRILE; TAXOID; TOLUENESULFONIC ACID DERIVATIVE; TRIPTORELIN;

AGED; BONE NEOPLASMS; COHORT ANALYSIS; DISEASE FREE SURVIVAL; HUMAN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDY; SECONDARY; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANDROSTENES; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BUSERELIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; FLUTAMIDE; HUMANS; LEUPROLIDE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NITRILES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TAXOIDS; TOSYL COMPOUNDS; TREATMENT OUTCOME; TRIPTORELIN PAMOATE;

EID: 84937634196     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1375-5     Document Type: Article

References (20)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, Investigators TAX (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512. doi:10.1056/NEJMoa040720
2. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, Investigators T (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154. doi:10.1016/S0140-6736(10)61389-X
3. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, Investigators C-A- (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005. doi:10.1056/NEJMoa1014618
4. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS, Investigators C-A (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992. doi:10.1016/S1470-2045(12)70379-0
5. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, Investigators A (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–1197. doi:10.1056/NEJMoa1207506
6. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzen L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, Investigators A (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223. doi:10.1056/NEJMoa1213755
7. Beer TM, Armstrong AJ, Sternberg CN, Higano CS, Iversen P, Loriot Y, Rathkopf DE, Bhattacharya S, Carles J, De Bono JS, Evans CP, Joshua AM, Kim C, Kimura G, Mainwaring PN, Mansbach HH, Miller K, Noonberg SB, Venner PM, Tombal B (2014) Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study. In: 2014 Genitourinary Cancers Symposium, J Clin Oncol 32, (suppl 4, abstract LBA1^), 2014
8. Huber J, Herpel E, Jakobi H, Hadaschik BA, Pahernik S, Hohenfellner M (2013) Two decades’ experience with a prospective biobank for urologic oncology: research, clinical care, and the patients’ view. Urol Oncol 31(7):990–996. doi:10.1016/j.urolonc.2012.01.016
9. Garcia-Albeniz X, Chan JM, Paciorek AT, Logan RW, Kenfield SA, Cooperberg MR, Caroll P, Hernan M (2014) Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. In: ASCO 2014, J Clin Oncol 32:5s, 2014 (suppl; abstr 5003)
10. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working G (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol Off J Am Soc Clin Oncol 26(7):1148–1159. doi:10.1200/JCO.2007.12.4487
11. Omlin A, Pezaro CJ, Zaidi S, Lorente D, Mukherji D, Bianchini D, Ferraldeschi R, Sandhu S, Dearnaley D, Parker C, Van As N, de Bono JS, Attard G (2013) Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. Br J Cancer 109(5):1079–1084. doi:10.1038/bjc.2013.446
12. Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS (2014) Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 50(1):78–84. doi:10.1016/j.ejca.2013.08.020
13. Gravanis I, Lopez AS, Hemmings RJ, Jimenez JC, Garcia-Carbonero R, Gallego IG, Gimenez EV, O’Connor D, Giuliani R, Salmonson T, Pignatti F (2013) The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 18(9):1032–1042. doi:10.1634/theoncologist.2013-0092
14. Goodman OB Jr, Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI (2013) Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. doi:10.1038/pcan.2013.41
15. van Soest RJ, de Morree ES, Shen L, Tannock IF, Eisenberger MA, de Wit R (2013) Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 Study. Eur Urol. doi:10.1016/j.eururo.2013.08.007
16. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368(14):1314–1325. doi:10.1056/NEJMoa1212299
17. Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F (2014) Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol 65(2):289–299. doi:10.1016/j.eururo.2013.08.008
18. Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gonen M, Fleisher M, Larson SM, Sawyers CL, Scher HI (2013) Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 31(28):3525–3530. doi:10.1200/JCO.2013.50.1684
19. van Soest RJ, van Royen ME, de Morree ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM (2013) Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 49(18):3821–3830. doi:10.1016/j.ejca.2013.09.026
20. Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, Hunt J, Sheridan E, Baikady B, Sarvadikar A, Maier G, Reid AH, Mulick Cassidy A, Olmos D, Attard G, de Bono J (2012) Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol Off J Euro Soc Med Oncol/ESMO 23(11):2943–2947. doi:10.1093/annonc/mds119